Atonomics achieves significant milestone related to performance data for Troponin I assay triggering scheduled payments from Beckman Coulter

Atonomics A/S announced today that it has achieved an important milestone related to a defined set of performance criteria for a Troponin I assay on the new Atolyzer® system.

Since entering an equity investment agreement with Beckman Coulter in May of last year to advance the Atolyzer® within cardiac testing, the company has worked diligently to deliver relevant Troponin I performance data.

“We are pleased to achieve this milestone,” said Thomas Warthoe, Atonomics’ CEO. “Troponin I is one of the most difficult assays to transfer to a near-patient system and still deliver data that are comparable to what the physicians get from the central laboratory; we believe the Atolyzer® has the potential to allow physicians in the future to continue to safely implement data from a near patient system.”

“We expect that this recent and significant achievement will generate appropriate interest from Industry in order to reach the full potential of the Atolyzer® platform”, said Ashok Dhanrajgir, Chairman of Atonomics board of directors and senior partner with Inventages Venture Capital

Atonomics’ majority shareholders are Inventages Venture Capital, Sunstone Capital, NeuroSearch A/S, and Beckman Coulter.

About Atonomics Atonomics is an emerging technology company based in Copenhagen, Denmark, that designs and manufactures the innovative Atolyzer® system for near-patient testing in hospitals, clinics, physician offices and patient monitoring. Atonomics is pursuing a strategy to partner with leading players in the industry to bring a new dimension of quality to the point-of-care market. The Atolyzer® system is a platform for immuno-diagnostic and molecular diagnostic testing. The Atolyzer® is designed for simplicity and ease of use while preserving performance and safety. The stand-alone device is operated with a single touch by any health worker and can be positioned in any location throughout the hospital, clinic or office where large systems cannot operate, representing true near-patient testing.

Trace® is now ready for ordering

€ 2495 Trace® device                
€ 15 each Lipids capsule  
€ 120 for 10 Lipids capsules

We will on a continuous basis release more and more important biomarker capsules.

Trace is available now for you that wishes to get started with this important biomarker monitoring device.


From 2018 we will have semi-automated important production procedures and thus can sell at a lower price. 

We allow you to pre-order now for below pricing with delivery time before end of April 2018.

€ 695 Trace® device
€ 15 each Lipids capsule or
€ 120 for 10 Lipids capsules

Orders will be shipped on a first incoming order basis.

Continue ordering